Article
Commercial gene expression tests for prostate cancer prognosis provide paradoxical estimates of race-specific risk
2019-04-12
Abstract excerpt
<h4>Background</h4> Commercial gene expression signatures of prostate cancer (PCa) prognosis were developed and validated in cohorts of predominantly European American men (EAM). Limited research exists on the value of such signatures in African American men (AAM), who have poor PCa outcomes. We explored differences in gene expression between EAM and AAM for three commercially available panels recommended by the...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 03e716bd-89fb-5ff9-9916-5f5f7c977005
- DOI
- 10.1101/604058
